Long‐Term Anti‐SARS‐CoV‐2 IgG Antibody Levels in Vaccinated Diabetes Patients After Recovery From COVID‐19

作者：Xiaoying Zhou, Wenjuan Wang, Yang Yuan, Shanhu Qiu, Yandong Cheng, Zilin Sun · 发表于：Diabetes/Metabolism Research and Reviews · 年份：2025 · DOI：10.1002/dmrr.70043 · 被引用次数：3 · 研究领域：SARS-CoV-2 and COVID-19 Research、Diabetes and associated disorders、COVID-19 Clinical Research Studies

BACKGROUND: Long-term persistence of anti-SARS-CoV-2 IgG antibodies is critical to protect against SARS-CoV-2 infection or to alleviate the severity of COVID-19. However, the persistence of anti-SARS-CoV-2 IgG after infection in vaccinated diabetes patients is unclear. This study aimed to investigate levels of anti-SARS-CoV-2 IgG 1 year after SARS-CoV-2 infection in diabetes patients. METHODS: This study was conducted between December 2023 and January 2024. Participants with SARS-CoV-2 infection during December 2022 to January 2023 were included, and were classified into the diabetes group and non-diabetes group. Anti-N/S IgG antibodies were measured with chemiluminescence immunoassay. RESULTS: AU/mL, p = 0.001). In vaccinated subjects, antibody levels in diabetes patients were also lower than those in non-diabetic patients. After adjustment for sex, age, body mass index, estimated glomerular filtration rate, hypertension, and heart disease, diabetes was negatively correlated with antibody titres (β = -0.16, 95% confidence interval (CI) -0.26 to -0.06, p = 0.002). In the diabetes group, after adjustment for confounders, use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) was positively associated with high antibody levels (odds ratio 3.84, 95% CI 1.70-8.65, p = 0.001). CONCLUSION: Vaccinated diabetes patients have lower anti-N/S IgG antibodies than non-diabetic patients 12 months after infection. SGLT-2i is associated with higher anti-N/S IgG antibody levels in diabete...